Clinical trial · Interventional
Assessment of Fatigue During Radiotherapy for Breast Cancer With and Without Homeopathy Treatment
Cognitive and Emotional Assessment of Fatigue During Radiotherapy for Breast Cancer With and Without Homeopathy Treatment
NCT02890316CI-TRIAL-00038015completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the effects of homeopathy treatment on radiotherapy-induced fatigue, cognitive and emotional functions.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Homeopathy remedy | Other | — | UNRESOLVED |
| Radiation as adjuvant therapy for breast cancer | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Radiation therapy with Homeopathy
- description
- Patients in this arm will receive the homeopathy remedy during the adjuvant radiation therapy period, from treatment number 16 until the last assessment, 3 times every day.
- interventionNames
- Other: Homeopathy remedy
- Radiation: Radiation as adjuvant therapy for breast cancer
- type
- PLACEBO_COMPARATOR
- label
- Radiation therapy with placebo
- description
- Patients in this arm will receive the placebo remedy during the adjuvant radiation period, from treatment number 16 until the last assessment, 3 times every day.
- interventionNames
- Radiation: Radiation as adjuvant therapy for breast cancer
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: 1. Female patients aged at least 18 years with unilateral breast cancer following chemotherapy. 2. Planned to receive 50 Gy whole breast irradiation and lymphatic basin + boost to tumor bed. 3. Capable of giving written informed consent following the instructions of receiving the study remedy or placebo. 4. No co-morbidities known to affect radiotherapy reactions. 5. No co-existing neurological or active psychiatric chronic diseases. 6. No evidence of infection or inflammation of breast to be treated. 7. Not receiving chemotherapy during radiotherapy course. Biological or hormonal therapy will be allowed during the study. Exclusion Criteria: 1. Uncontrolled hypertension. 2. Participating in another clinical study with active treatment 3. Substance abuse. 4. Intellectual disabilities. 5. Unable to sign informed concent
References
Publications (1)
- DERIVEDDolev T, Ben-David M, Shahadi I, Freed Y, Zubedat S, Aga-Mizrachi S, Brand Z, Galper S, Jacobson G, Avital A. Attention Dysregulation in Breast Cancer Patients Following a Complementary Alternative Treatment Routine: A Double-Blind Randomized Trial. Integr Cancer Ther. 2021 Jan-Dec;20:15347354211019470. doi: 10.1177/15347354211019470. PMID 34027702